VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $160,345,304 | +1.5% | 3,145,259 | -0.6% | 0.01% | +12.5% |
| Q2 2023 | $157,975,801 | +37.0% | 3,163,312 | +2.8% | 0.01% | +14.3% |
| Q1 2023 | $115,289,080 | -62.1% | 3,076,016 | -51.5% | 0.01% | -22.2% |
| Q4 2022 | $303,809,378 | +535.1% | 6,335,962 | +217.9% | 0.01% | +200.0% |
| Q3 2022 | $47,833,000 | +18.5% | 1,993,036 | +7.4% | 0.00% | +50.0% |
| Q2 2022 | $40,379,000 | +20.8% | 1,855,644 | +34.1% | 0.00% | 0.0% |
| Q1 2022 | $33,428,000 | +19.6% | 1,384,168 | +17.8% | 0.00% | +100.0% |
| Q4 2021 | $27,952,000 | -3.0% | 1,174,931 | +3.4% | 0.00% | -50.0% |
| Q3 2021 | $28,827,000 | -14.8% | 1,136,254 | -24.4% | 0.00% | 0.0% |
| Q2 2021 | $33,838,000 | -3.3% | 1,503,263 | -15.2% | 0.00% | 0.0% |
| Q1 2021 | $34,999,000 | +42.9% | 1,772,076 | +92.2% | 0.00% | +100.0% |
| Q4 2020 | $24,493,000 | +81.0% | 921,830 | +236.4% | 0.00% | 0.0% |
| Q3 2020 | $13,532,000 | – | 274,041 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $100,049,000 | 34.21% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $45,299,000 | 18.86% |
| Pivotal bioVenture Partners Investment Advisor LLC | 776,039 | $18,625,000 | 6.81% |
| Kynam Capital Management, LP | 698,638 | $16,767,000 | 3.53% |
| GREAT POINT PARTNERS LLC | 600,000 | $14,400,000 | 3.47% |
| Frazier Life Sciences Management, L.P. | 1,547,405 | $37,138,000 | 2.86% |
| Ghost Tree Capital, LLC | 360,000 | $8,640,000 | 2.42% |
| RA Capital Management | 4,581,203 | $109,949,000 | 2.35% |
| Opaleye Management Inc. | 190,000 | $4,560,000 | 1.88% |
| TPG GP A, LLC | 3,285,504 | $78,852,000 | 1.29% |